Celgene prices $4.5B senior notes to help buy Juno; Health Affairs study says Novartis prices its CAR-T too high

→ Celgene $CELG has priced four series of senior unsecured notes for an aggregate of $4.5 billion, a portion of which will be used to pay for a slice of its $9 billion acquisition of Juno Therapeutics (announced in January). Of the new notes, $500 million will mature in 2021 with an annual interest rate of 2.875%, $1 billion will mature in 2023 at 3.25%. $1.5 billion will mature in 2028 at 3.9%, and $1.5 billion will mature in 2048 at 4.55%.

A new study published in Health Affairs concluded that Novartis should’ve priced its pioneering CAR-T Kymriah at a level far below the $450,000 figure that it went with. The authors — two of whom have incurable blood cancers — crunched the numbers and came up with $160,000, which they felt would be more fair. “(I)f patients like us cannot afford the drug, then this hope is pointless.”

The best place to read Endpoints News? In your inbox.

Comprehensive daily news report for those who discover, develop, and market drugs. Join 42,100+ biopharma pros who read Endpoints News by email every day.

Free Subscription

Head of Business Development
Wren Therapeutics Boston, MA
Life Sciences Venture Professional
Northpond Ventures Washington, DC
Senior Drug Discovery Oncologist
Schrödinger New York, NY

Visit Endpoints Careers ->